Drug Type Dual payload Antibody drug conjugate (Dual payload ADC), Diagnostic radiopharmaceuticals |
Synonyms 89 Zr-labeled T-DM1 |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC35H48ClN3O10S |
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N |
CAS Registry139504-50-0 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Breast Cancer | Preclinical | Canada | 21 Sep 2016 |






